BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BNTX BioNTech SE

163.69

+0.69

+0.42%

最高--	最低--	成交量54.90万
今开--	昨收163.00	日振幅3.28%
总市值397.80亿	流通市值145.97亿	总股本2.43亿
成交额9,021万	换手率0.62%	流通股本8,918万
市净率2.34	ROE--	每股收益47.97
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

Data provider: Ningxia XSRK Technology Limited

{"market":"US","stockBase":{"symbol":"BNTX","market":"US","secType":"STK","nameCN":"BioNTech SE","latestPrice":163.69,"timestamp":1653328822682,"preClose":163,"halted":0,"volume":549022,"delay":0,"change":0.69,"changeRate":0.004233,"floatShares":89177651,"shares":243019216,"eps":54.873013,"lyrEps":47.97268,"pbRate":2.34,"psRate":1.6,"amount":90213631.50334,"amplitude":0.032761,"volumeRatio":0.63873,"dividePrice":0,"prevYearClose":257.8,"fiveDayClose":151.2,"twentyDayClose":155.1},"adData":{"groupTypeList":[],"userSplitList":[]},"requestUrl":"/m/hq/s/BNTX","defaultTab":"news","newsList":[{"id":"2237334353","title":"君实生物(688180.SH)：新冠药VV116对比PAXLOVID早期治疗轻中度COVID-19的III期注册临床研究达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2237334353","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2237334353?lang=zh_CN&edition=full","pubTime":"2022-05-23 22:59","pubTimestamp":1653317954,"startTime":"0","endTime":"0","summary":"NCT05341609研究是一项多中心、单盲、随机、对照III期临床研究，旨在评价VV116对比奈玛特韦片/利托那韦片用于轻中度COVID19患者早期治疗的有效性和安全性。该临床研究结果显示，VV116用于轻中度COVID-19的早期治疗达到临床方案预设的主要终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/727790.html","is_publish_highlight":false},{"id":"2237535835","title":"君实生物：VV116用于轻中度 COVID-19 的早期治疗达到临床方案预...","url":"https://stock-news.laohu8.com/highlight/detail?id=2237535835","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2237535835?lang=zh_CN&edition=full","pubTime":"2022-05-23 22:58","pubTimestamp":1653317918,"startTime":"0","endTime":"0","summary":"君实生物：VV116用于轻中度 COVID-19 的早期治疗达到临床方案预设的主要终点，将于近期与药物监管部门沟通递交新药上市申请事宜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-23/doc-imizirau4395444.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-23/doc-imizirau4395444.shtml","is_publish_highlight":false},{"id":"2237331031","title":"君实生物(01877)：VV116对比PAXLOVID早期治疗轻中度COVID-19的III期注册临床研究达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2237331031","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2237331031?lang=zh_CN&edition=full","pubTime":"2022-05-23 22:56","pubTimestamp":1653317787,"startTime":"0","endTime":"0","summary":"智通财经APP讯，君实生物(01877)发布公告，公司控股子公司上海君拓生物医药科技有限公司与苏州旺山旺水生物医药有限公司合作开发的产品口服核苷类抗SARS-CoV-2药物VV116片(项目代号： JT001/VV116，“VV116”)在一项对比奈玛特韦片╱利托那韦片(即PAXLOVID)用于轻中度新型冠状病毒肺炎早期治疗的III期注册临床研究 (NCT05341609)达到方案预设的主要终点。公司将于近期与监管部门沟通递交新药上市申请事宜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/727788.html","is_publish_highlight":false},{"id":"2236576187","title":"奥雷巴替尼有治疗新冠潜力 最新研究成果发文国际权威期刊《EMBO分子医学》","url":"https://stock-news.laohu8.com/highlight/detail?id=2236576187","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2236576187?lang=zh_CN&edition=full","pubTime":"2022-05-18 22:05","pubTimestamp":1652882700,"startTime":"0","endTime":"0","summary":"奥雷巴替尼可以通过阻断其中的大多数激酶来抑制NTD诱导的PBMCs中细胞因子释放，从而缓解炎症。目前，奥雷巴替尼治疗CML、急性淋巴细胞白血病、以及胃肠间质瘤等的临床研究正在中国、美国等地快速开展。此次在《EMBO分子医学》杂志发表的奥雷巴替尼的临床前研究结果首次揭示了该药物在新冠治疗领域的极大潜力，具有非常重大的意义。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://wwwold.prnasia.com/story/archive/3761863_ZH61863_1","is_publish_highlight":false},{"id":"2236226291","title":"美股异动 | 抗疫概念股走高 BioNTech SE(BNTX.US)涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2236226291","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2236226291?lang=zh_CN&edition=full","pubTime":"2022-05-17 23:34","pubTimestamp":1652801667,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月17日(周二)，抗疫概念股走高，截至发稿，Ocugen(OCGN.US)涨超8%，BioNTech SE(BNTX.US)涨超5%，诺瓦瓦克斯医药(NVAX.US)涨超4%，Vir Biotechnology(VIR.US)涨近4%，Moderna(MRNA.US)涨超3%，辉瑞(PFE.US)涨1.40%。早前，美国食品药品监督管理局扩大辉瑞/BioNTech SE新冠疫苗加强剂的适用范围，使其适用于5至11岁的儿童。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/725025.html","is_publish_highlight":false},{"id":"2236547245","title":"瑞银集团：将BioNTech(BNTX.O)目标价从170美元下调至168...","url":"https://stock-news.laohu8.com/highlight/detail?id=2236547245","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2236547245?lang=zh_CN&edition=full","pubTime":"2022-05-17 18:24","pubTimestamp":1652783044,"startTime":"0","endTime":"0","summary":"瑞银集团：将BioNTech(BNTX.O)目标价从170美元下调至168美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-17/doc-imcwipik0374958.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-17/doc-imcwipik0374958.shtml","is_publish_highlight":false},{"id":"2236807234","title":"BioNTech SE(BNTX.O)：公司2022年的收入指引和2022...","url":"https://stock-news.laohu8.com/highlight/detail?id=2236807234","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2236807234?lang=zh_CN&edition=full","pubTime":"2022-05-16 19:49","pubTimestamp":1652701745,"startTime":"0","endTime":"0","summary":"BioNTech SE(BNTX.O)：公司2022年的收入指引和2022年向欧盟成员国提供的全年疫苗剂量承诺保持不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-16/doc-imcwipik0195177.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-16/doc-imcwipik0195177.shtml","is_publish_highlight":false},{"id":"2234960676","title":"全球新冠最长随访：逾千名金银潭出院患者2年后超半数仍有后遗症","url":"https://stock-news.laohu8.com/highlight/detail?id=2234960676","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2234960676?lang=zh_CN&edition=full","pubTime":"2022-05-12 06:30","pubTimestamp":1652308200,"startTime":"0","endTime":"0","summary":"中国团队的一项最新研究报道了不同严重程度的新冠住院幸存者在急性COVID-19感染后2年内健康结局的纵向演变。研究提到，2020年1月7日至2020年5月29日期间，武汉金银潭医院COVID-19患者出院共计2469例。随访时间包括6个月、12个月和2年。COVID-19患者也更有可能报告一些其他症状，包括关节疼痛、心悸、头晕和头痛。研究团队最后总结称，无论最初疾病的严重程度如何，COVID-19出院患者的身心健康随着时间都有改善，大多数人在2年内也重返了工作岗位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2022-05-12/doc-imcwiwst6925651.shtml?finpagefr=p_115","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://finance.sina.com.cn/jjxw/2022-05-12/doc-imcwiwst6925651.shtml?finpagefr=p_115","is_publish_highlight":false},{"id":"2234636665","title":"BioNTech SE CEO Ugur Sahin：针对变种疫苗的监管路...","url":"https://stock-news.laohu8.com/highlight/detail?id=2234636665","media":"媒体滚动","top":-1,"share":"https://www.laohu8.com/m/news/2234636665?lang=zh_CN&edition=full","pubTime":"2022-05-09 20:56","pubTimestamp":1652101009,"startTime":"0","endTime":"0","summary":"BioNTech SE CEO Ugur Sahin：针对变种疫苗的监管路径尚不清楚。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina_symbol","url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-09/doc-imcwipii8928306.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://cj.sina.cn/article/normal_detail?url=https://finance.sina.com.cn/7x24/2022-05-09/doc-imcwipii8928306.shtml","is_publish_highlight":false},{"id":"2234782523","title":"BioNTech(BNTX.US)Q1净利润同比增长228%至36.99亿欧元 重申全年业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2234782523","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2234782523?lang=zh_CN&edition=full","pubTime":"2022-05-09 19:12","pubTimestamp":1652094737,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月9日(周一)美股盘前，BioNTech公布了2022年第一季度财务业绩。财报显示，BioNTech一季度营收为63.75亿欧元，上年同期为20.48亿欧元，同比增长211%;净利润为36.99亿欧元，上年同期为11.28亿欧元，同比增长228%;摊薄后每股收益为14.24欧元，上年同期为4.39欧元。截至发稿，BioNTech周一美股盘前跌0.51%，报135.48美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/720516.html","is_publish_highlight":false},{"id":"1112747511","title":"BioNtech SE Q1营收、净利润均超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1112747511","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1112747511?lang=zh_CN&edition=full","pubTime":"2022-05-09 18:01","pubTimestamp":1652090498,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","source_url":"","is_publish_highlight":false},{"id":"1123185258","title":"BioNTech盘前涨超3%，一季度营收、净利超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1123185258","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1123185258?lang=zh_CN&edition=full","pubTime":"2022-05-09 17:20","pubTimestamp":1652088018,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://static.tigerbbs.com/212c2d22f63757fd3779547854894fca","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/212c2d22f63757fd3779547854894fca"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","source_url":"","is_publish_highlight":true},{"id":"2233858792","title":"制造同意、散布仇恨：提防“计算宣传”","url":"https://stock-news.laohu8.com/highlight/detail?id=2233858792","media":"虎嗅","top":-1,"share":"https://www.laohu8.com/m/news/2233858792?lang=zh_CN&edition=full","pubTime":"2022-05-05 09:44","pubTimestamp":1651715045,"startTime":"0","endTime":"0","summary":"你看到的“发言”，未必是真实的“舆论”","market":"hk","thumbnail":"https://img.huxiucdn.com/article/cover/202205/05/084752039987.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg","type":0,"news_type":0,"thumbnails":["https://img.huxiucdn.com/article/cover/202205/05/084752039987.jpg?imageView2/1/w/720/h/405/|imageMogr2/strip/interlace/1/quality/85/format/jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.huxiu.com/article/546132.html","is_publish_highlight":false},{"id":"2232702135","title":"新型冠状病毒在韩国迎来家庭之月，掀起了“新文化景观”","url":"https://stock-news.laohu8.com/highlight/detail?id=2232702135","media":"美通社","top":-1,"share":"https://www.laohu8.com/m/news/2232702135?lang=zh_CN&edition=full","pubTime":"2022-05-04 18:02","pubTimestamp":1651658520,"startTime":"0","endTime":"0","summary":"韩国首尔2022年5月4日 /美通社/ -- 在韩国，5月被称为“家庭月”。CheongKwanJang    由于长期的COVID-19大流行，家庭月正在发生变化。第一选择是“现金”，其次是红参等“健康食品”。此外，红参通过激活巨噬细胞来帮助增强免疫力，从而杀死病毒。红参的好处已得到韩国食品药品安全部的正式认可，食品药品安全部是韩国监管食品药品安全的部门。据清官庄的销售分析，被称为“家庭之月”的5月，以中年人为对象的红参产品是孩子们为父母购买的人气礼物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://wwwold.prnasia.com/story/archive/3744445_ZH44445_1","is_publish_highlight":false},{"id":"1143097557","title":"美国抗疫概念股走高，Moderna涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143097557","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1143097557?lang=zh_CN&edition=full","pubTime":"2022-05-02 21:53","pubTimestamp":1651499617,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"https://static.tigerbbs.com/a8c5a31a8c3891917dc4c14d9c98b9de","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a8c5a31a8c3891917dc4c14d9c98b9de"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","source_url":"","is_publish_highlight":true},{"id":"2231259432","title":"Biontech Se盘中异动 大幅下挫5.00%报147.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2231259432","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2231259432?lang=zh_CN&edition=full","pubTime":"2022-04-30 00:18","pubTimestamp":1651249114,"startTime":"0","endTime":"0","summary":"北京时间2022年04月26日23时18分，Biontech Se股票出现波动，股价大幅下跌5.00%。截至发稿，该股报147.35美元/股，成交量41.1658万股，换手率0.17%，振幅5.11%。Biontech Se股票所在的生物技术行业中，整体跌幅为1.51%。Biontech Se公司简介：BioNTech是一家总部位于德国的生物技术公司，专注于开发癌症治疗药物，包括个体化免疫疗法，以及包括COVID-19在内的传染病疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202204300018377bfe643d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202204300018377bfe643d&s=b","is_publish_highlight":false},{"id":"2231473111","title":"君实生物(01877)：正在进行临床研究以评估VV116用于早期治疗轻度至中度COVID-19患者的有效性","url":"https://stock-news.laohu8.com/highlight/detail?id=2231473111","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2231473111?lang=zh_CN&edition=full","pubTime":"2022-04-29 06:59","pubTimestamp":1651186763,"startTime":"0","endTime":"0","summary":"2022年4月，香港中文大学(中大)临床研究中心宣布与中大医院合作进行临床研究，以评估VV116用于早期治疗轻度至中度COVID-19患者的有效性。基于该试验的积极结果，VV116已在乌兹别克斯坦获得批准用于中重度COVID-19患者的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/715711.html","is_publish_highlight":false},{"id":"2230485723","title":"Biontech Se盘中异动 大幅下挫5.00%报147.35美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2230485723","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2230485723?lang=zh_CN&edition=full","pubTime":"2022-04-26 23:18","pubTimestamp":1650986337,"startTime":"0","endTime":"0","summary":"北京时间2022年04月26日23时18分，Biontech Se股票出现波动，股价大幅下跌5.00%。截至发稿，该股报147.35美元/股，成交量41.1658万股，换手率0.17%，振幅5.11%。Biontech Se股票所在的生物技术行业中，整体跌幅为1.51%。Biontech Se公司简介：BioNTech是一家总部位于德国的生物技术公司，专注于开发癌症治疗药物，包括个体化免疫疗法，以及包括COVID-19在内的传染病疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202204262318577a6ea618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202204262318577a6ea618&s=b","is_publish_highlight":false},{"id":"2230127199","title":"《柳叶刀》智能设备预测新冠不靠谱","url":"https://stock-news.laohu8.com/highlight/detail?id=2230127199","media":"视频","top":-1,"share":"https://www.laohu8.com/m/news/2230127199?lang=zh_CN&edition=full","pubTime":"2022-04-26 08:12","pubTimestamp":1650931950,"startTime":"0","endTime":"0","summary":"在COVID-19大流行的早期，智能手表的倡导者和可穿戴技术公司认为这些设备可以帮助检测疾病。他们想通过心率和氧气水平等东西来标记可能患病的人。根据上周发表在《柳叶刀》上的一篇新评论，该策略仍可能是跟踪疾病的一种合理方式，但两年后，这一承诺并没有得到证实--研...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://mobile.zol.com.cn/791/7912726.html","is_publish_highlight":false},{"id":"1107412021","title":"美国抗疫概念股走高，BioNTech SE涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107412021","media":"老虎资讯综合","top":-1,"share":"https://www.laohu8.com/m/news/1107412021?lang=zh_CN&edition=full","pubTime":"2022-04-25 21:39","pubTimestamp":1650893974,"startTime":"0","endTime":"0","summary":"","market":"other","thumbnail":"https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5ce7e4c84e3c54b81fbaee9cb1c77ad9"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","source_url":"","is_publish_highlight":true}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0262},{"period":"1month","weight":0.0606},{"period":"3month","weight":0.0386},{"period":"6month","weight":-0.4374},{"period":"1year","weight":-0.1998},{"period":"ytd","weight":-0.3677}],"websiteUrl":"http://www.biontech.de","compareEarnings":[{"period":"1week","weight":-0.0301},{"period":"1month","weight":-0.1239},{"period":"3month","weight":-0.1027},{"period":"6month","weight":-0.169},{"period":"1year","weight":-0.0618},{"period":"ytd","weight":-0.1797}],"name":"BioNTech SE","description":"BioNTech SE成立于2008年6月2日。该公司结合了数十年的免疫学，尖端治疗平台以及各种患者分析和生物信息学工具的开创性研究，开发针对癌症和其他疾病的个体化免疫疗法。该公司利用强大的新治疗机制，利用各种生物学靶点，利用每位患者免疫系统的力量，解决每位患者潜在疾病的独特分子特征。","exchange":"NASDAQ","nameEN":"BioNTech SE","compareStock":{"symbol":"SPY","name":"标普500ETF"}},"isWeiXinMini":false,"pagemeta":{"title":"BioNTech SE(BNTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioNTech SE(BNTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioNTech SE,BNTX,BioNTech SE股票,BioNTech SE股票老虎,BioNTech SE股票老虎国际,BioNTech SE行情,BioNTech SE股票行情,BioNTech SE股价,BioNTech SE股市,BioNTech SE股票价格,BioNTech SE股票交易,BioNTech SE股票购买,BioNTech SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情"}}